Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1755)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (13)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4172)
  2. Weinberg Fellows (2756)
  3. Hematologic Malignancies, Division of (2492)
  4. Solid Tumor Oncology Division (2422)
  5. Center for Hematologic Malignancies (1945)
  6. GSK Faculty (1879)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (343)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (358)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4491)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
    Meeting Abstract

    Carneiro, B. A.; Rosen, E.; Fontana, E.; Lee, E. K.; Mettu, N. B.; Lheureux, S.; Plummer, R.; Silverman, I. M.; Schonhoft, J. D.; Yang, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
    Meeting Abstract

    Guo, R.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
    Meeting Abstract

    Vieito, M.; McKean, M.; Spira, A. I.; Rosen, E.; Rodon, J.; Garcia, V. M.; Gambardella, V.; Saavedra, O.; Cousin, S.; Cassier, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
    Meeting Abstract

    Tsai, C.; An, J. A. R.; Cabel, L.; Brannon, A. R.; Moiso, E.; Gedvilaite, E.; Ahmed, M.; Loudon, L.; Weipert, C.; Chou, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
    Meeting Abstract

    Cabel, L.; An, J. A. R.; Kurtz, D.; Ross, D.; Dikoglu, E.; Chen, Y.; Murphy, K.; Szuhany, K.; Stowell, S. L.; Maloney, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER plus metastatic breast cancer
    Meeting Abstract

    Rosen, E.; Caswell-Jin, J.; Berz, D.; Mai, N.; Fulgar, G.; Densel, M.; Chiang, G.; Sperry, S.; Warner, D.; Meric-Bernstam, F.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity
    Meeting Abstract

    Thorball, C. W.; Quandt, Z.; Saha, A.; Yao, L.; Midda, P.; Xu, Y.; Bejan, C. A.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Meeting Abstract

    Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Altered RNA splicing and AML therapy resistance
    Meeting Abstract

    Wang, E.; Pineda, J.; Kim, W.; Chen, S.; Bourcier, J.; Stahl, M.; Hogg, S.; Knorr, K.; Stanley, R.; Bradley, R.; more...
    Cancer Science (2024)

    Fulltext@MSK | Save